A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.

Satoshi HamauchiJunji FuruseToshimi TakanoYoshinori MunemotoKen FuruyaHideo BabaManabu TakeuchiYasuhiro ChodaTakashi HigashiguchiTateaki NaitoKei MuroKoichi TakayamaShusuke OyamaToru TakiguchiNaoyuki KomuraKazuo Tamura

Published in: Cancer (2019)

ANAM improved anorexia and patients' nutritional status, resulting in rapid increases in LBM and body weight in patients with advanced gastrointestinal cancer who had cancer cachexia. ANAM treatment was well tolerated over 12 weeks. ANAM is a potential clinically beneficial pharmacotherapeutic option for patients with advanced gastrointestinal cancer who have cancer cachexia.

Keyphrases

papillary thyroid
squamous cell
body weight
open label
randomized controlled trial
squamous cell carcinoma
lymph node metastasis
radiation therapy
newly diagnosed
young adults
cross sectional
prognostic factors
study protocol
patient reported outcomes